Currently out of the existing stock ratings of Matthew Sykes, 51 are a HOLD (34.23%), 79 are a BUY (53.02%), 19 are a SELL (12.75%).

Matthew Sykes

Work Performance Price Targets & Ratings Chart

Analyst Matthew Sykes works at GOLDMAN SACHS with a stock forecast success ratio of 51.05% fulfilled within 72.44 days on average. Previously, Matthew Sykes worked at GOLDMAN.

Matthew Sykes’s has documented 290 price targets and ratings displayed on 32 stocks. The coverage is on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on PACB, Pacific Biosciences of California at 19-Apr-2024.

Wall Street Analyst Matthew Sykes

Analyst best performing recommendations are on ZY (ZYMERGEN).
The best stock recommendation documented was for ZY (ZYMERGEN) at 8/4/2021. The price target of $12 was fulfilled within 1 day with a profit of $3.75 (45.45%) receiving and performance score of 454.55.

Average potential price target upside

of $77.33 (15.84%) on TMO (THERMO FISHER SCIENTIFIC).
of $23.91 (12.04%) on DHR (DANAHER).
of $18.34 (15.31%) on A (AGILENT TECHNOLOGIES).

DHR Danaher MRVI Maravai Lifesciences Holdings NAUT Nautilus Biotechnology NTRA Natera NVTA Invitae Corp PKI PerkinElmer TMO Thermo Fisher Scientific TXG 10X Genomics WAT Waters ZY Zymergen OMIC Singular Genomics Systems GH Guardant Health MYGN Myriad Genetics NEO NeoGenomics QTRX Quanterix Corp CTKB Cytek Biosciences HLTH Cue Health OLK Olink Holding AB ADR TX Ternium SA ADR CDNA Caredx MTD Mettler-Toledo International SMFR Sema4 Holdings Corp AVTR Avantor EXAS EXACT Sciences BRKR Bruker LMDX LumiraDx Ltd TWST Twist Bioscience Corp A Agilent Technologies DNA Ginkgo Bioworks Holdings QGEN Qiagen NV VCYT Veracyte PACB Pacific Biosciences of California

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Luke Sergott (BARCLAYS)